Piśmiennictwo
1. Diagnostyka i leczenie raka tarczycy – rekomendacje polskie. Endokrynologia Polska Tom 61; Nr 5/2010; 518-568
2. Nikiforov YE, Biddinger PW, Thompson LDR – Diagnostic pathology and molecular genetics of the thyroid; Wolters Kluwer/Lippincott Williams & Wilkins, 2009
3. Stewart BW Kleihues P. World Cancer Report. Lyon: IACR Press 2003
4. Białek EJ Jakubowski W. Ultrasonograficzna diagnostyka tarczycy, przytarczyc i węzłów chłonnych szyi, Warszawa-Zamość 2004
5. Rzepka A, Cissewski K, Olbricht T et al. Effectiveness of profilactic therapy on goiter recurrence in an area with low iodine intake – a sonographic follow-up study. Clinical Investigations 1994; (72):967-970
6. Ringel MD, Nabhan F. Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies; JCEM 2013; 98 (8):3104-3110
7. Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer; JCEM 2011; 96 (10):1283-1291
8. Robbins RJ, Schlumberger MJ. The evolving role of 131I for the treatment of differentiated thyroid carcinoma; J Nucl Med, 2005; 46 (1):28S-37S